The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-31
DOI
10.1186/s13045-020-00949-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
- (2020) F. Coussy et al. Journal of Hematology & Oncology
- Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
- (2020) Ufuk Degirmenci et al. Cells
- Targeting ERK-Hippo Interplay in Cancer Therapy
- (2020) Karel Vališ et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
- (2020) Xi Yuan et al. Molecular Oncology
- RAS, wanted dead or alive: Advances in targeting RAS mutant cancers
- (2020) Clint A. Stalnecker et al. Science Signaling
- Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
- (2020) Michael J. Bond et al. ACS Central Science
- MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival
- (2019) Chih-Shia Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- AMP-activated protein kinase: the current landscape for drug development
- (2019) Gregory R. Steinberg et al. NATURE REVIEWS DRUG DISCOVERY
- Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
- (2019) Conan G. Kinsey et al. NATURE MEDICINE
- Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
- (2019) Kirsten L. Bryant et al. NATURE MEDICINE
- EGF receptor and PKCδ kinase activate DNA damage–induced pro-survival and pro-apoptotic signaling via biphasic activation of ERK and MSK1 kinases
- (2019) Angela M. Ohm et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF
- (2019) Amber Y. Gunderwala et al. ACS Chemical Biology
- V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer
- (2019) Yijun Gao et al. Cancer Discovery
- RAS Mutations Are Not Created Equal
- (2019) G. Aaron Hobbs et al. Cancer Discovery
- The strange case of AMPK and cancer: Dr Jekyll or Mr Hyde?
- (2019) Diana Vara-Ciruelos et al. Open Biology
- Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
- (2019) Jiajun Yap et al. Jove-Journal of Visualized Experiments
- AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells
- (2019) Jimena Trillo-Tinoco et al. CANCER RESEARCH
- Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases
- (2019) Yasushi Kondo et al. SCIENCE
- Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition
- (2019) Meagan B. Ryan et al. CLINICAL CANCER RESEARCH
- Architecture of autoinhibited and active BRAF–MEK1–14-3-3 complexes
- (2019) Eunyoung Park et al. NATURE
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- AMPK promotes survival of c‐Myc‐positive melanoma cells by suppressing oxidative stress
- (2018) Alain Kfoury et al. EMBO JOURNAL
- The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking the phospho-Ser-621 in the carboxyl-terminus of CRAF
- (2018) Jimin Yuan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
- (2018) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function
- (2018) Lixin Wan et al. MOLECULAR CELL
- AMP kinase promotes glioblastoma bioenergetics and tumour growth
- (2018) Rishi Raj Chhipa et al. NATURE CELL BIOLOGY
- The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants
- (2018) Jimin Yuan et al. ONCOGENE
- Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms
- (2018) Annan Yang et al. Cancer Discovery
- Targeting the MAPK Pathway in RAS Mutant Cancers
- (2018) Sarah G. Hymowitz et al. Cold Spring Harbor Perspectives in Medicine
- Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers
- (2018) Jeffrey A. Knauf et al. JOURNAL OF CLINICAL INVESTIGATION
- Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer
- (2018) Di Wu et al. NATURE
- RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
- (2018) Robert J. Nichols et al. NATURE CELL BIOLOGY
- Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways
- (2018) Benoît Tessoulin et al. Journal of Hematology & Oncology
- RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
- (2018) Zhan Yao et al. NATURE MEDICINE
- Fibroblast growth factor receptors as treatment targets in clinical oncology
- (2018) Masaru Katoh Nature Reviews Clinical Oncology
- The ERK and JNK pathways in the regulation of metabolic reprogramming
- (2018) Salvatore Papa et al. ONCOGENE
- Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis
- (2018) Jimin Yuan et al. Science Signaling
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
- (2018) Sunilkumar Kakadia et al. OncoTargets and Therapy
- Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells
- (2018) Arun M Unni et al. eLife
- Genomics of Hairy Cell Leukemia
- (2017) Enrico Tiacci et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- (2017) David Planchard et al. LANCET ONCOLOGY
- Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK
- (2017) Chen-Song Zhang et al. NATURE
- RAF1/BRAF dimerization integrates the signal from RAS to ERK and ROKα
- (2017) Andrea Varga et al. Science Signaling
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- (2017) Ryan J. Sullivan et al. Cancer Discovery
- A Role for Mitochondrial Translation in Promotion of Viability in K-Ras Mutant Cells
- (2017) Timothy D. Martin et al. Cell Reports
- A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution
- (2017) Grace R. Anderson et al. Cell Reports
- Synthetic Lethal Vulnerabilities in KRAS -Mutant Cancers
- (2017) Andrew J. Aguirre et al. Cold Spring Harbor Perspectives in Medicine
- RAF1/BRAF dimerization integrates the signal from RAS to ERK and ROKα
- (2017) Andrea Varga et al. Science Signaling
- Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non–Small-Cell Lung Cancer With Brain Metastases
- (2017) Pablo Martínez et al. JAMA Oncology
- AMPK regulates autophagy by phosphorylating BECN1 at threonine 388
- (2016) Deyi Zhang et al. Autophagy
- Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells
- (2016) Zhen Li et al. CANCER LETTERS
- A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
- (2016) Sai Krishna Athuluri-Divakar et al. CELL
- B-Raf activation loop phosphorylation revisited
- (2016) Martin Köhler et al. CELL CYCLE
- AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival
- (2016) Rigel J. Kishton et al. Cell Metabolism
- The ERK cascade inhibitors: Towards overcoming resistance
- (2016) Galia Maik-Rachline et al. DRUG RESISTANCE UPDATES
- AMP-activated protein kinase: a cellular energy sensor that comes in 12 flavours
- (2016) Fiona A. Ross et al. FEBS Journal
- Recent insights into the function of autophagy in cancer: Table 1.
- (2016) Ravi Amaravadi et al. GENES & DEVELOPMENT
- Autophagy provides metabolic substrates to maintain energy charge and nucleotide pools in Ras-driven lung cancer cells
- (2016) Jessie Yanxiang Guo et al. GENES & DEVELOPMENT
- RAS isoforms and mutations in cancer at a glance
- (2016) G. Aaron Hobbs et al. JOURNAL OF CELL SCIENCE
- Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
- (2016) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolving molecularly targeted therapies for advanced-stage thyroid cancers
- (2016) Keith C. Bible et al. Nature Reviews Clinical Oncology
- From tumour heterogeneity to advances in precision treatment of colorectal cancer
- (2016) Cornelis J. A. Punt et al. Nature Reviews Clinical Oncology
- AMPK promotes tolerance to Ras pathway inhibition by activating autophagy
- (2016) S Sanduja et al. ONCOGENE
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- AMP-activated protein kinase mediates mitochondrial fission in response to energy stress
- (2016) E. Q. Toyama et al. SCIENCE
- AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs
- (2016) D. Grahame Hardie et al. TRENDS IN CELL BIOLOGY
- Evolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer
- (2016) Biplab Dasgupta et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- A systems study reveals concurrent activation of AMPK and mTOR by amino acids
- (2016) Piero Dalle Pezze et al. Nature Communications
- Progress on Covalent Inhibition of KRASG12C
- (2016) K. D. Westover et al. Cancer Discovery
- BRAFV600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells
- (2016) Toshinori Sueda et al. Scientific Reports
- Amino acids and autophagy: their crosstalk, interplay and interlock
- (2015) Chien-An A. Hu et al. AMINO ACIDS
- Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes
- (2015) Ana Herrero et al. CANCER CELL
- Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
- (2015) Sheng-Bin Peng et al. CANCER CELL
- Degradation of AMPK by a Cancer-Specific Ubiquitin Ligase
- (2015) Carlos T. Pineda et al. CELL
- Global Phosphoproteomic Analysis of Human Skeletal Muscle Reveals a Network of Exercise-Regulated Kinases and AMPK Substrates
- (2015) Nolan J. Hoffman et al. Cell Metabolism
- AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow
- (2015) Yusuke Saito et al. Cell Stem Cell
- Motif affinity and mass spectrometry proteomic approach for the discovery of cellular AMPK targets: Identification of mitochondrial fission factor as a new AMPK substrate
- (2015) Serge Ducommun et al. CELLULAR SIGNALLING
- RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
- (2015) J. Downward CLINICAL CANCER RESEARCH
- MicroRNA-455 regulates brown adipogenesis via a novel HIF1an-AMPK-PGC1 signaling network
- (2015) H. Zhang et al. EMBO REPORTS
- Recent advances in RASopathies
- (2015) Yoko Aoki et al. JOURNAL OF HUMAN GENETICS
- BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers
- (2015) Z. Tang et al. MOLECULAR CANCER THERAPEUTICS
- RAF inhibitors that evade paradoxical MAPK pathway activation
- (2015) Chao Zhang et al. NATURE
- Regulation of RAF protein kinases in ERK signalling
- (2015) Hugo Lavoie et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma
- (2015) X. Xie et al. Cancer Discovery
- Melanoma
- (2015) Dirk Schadendorf et al. Nature Reviews Disease Primers
- Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling
- (2014) Jacob R. Haling et al. CANCER CELL
- ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
- (2014) E. M. Goetz et al. CANCER RESEARCH
- AMPK Reverses the Mesenchymal Phenotype of Cancer Cells by Targeting the Akt–MDM2–Foxo3a Signaling Axis
- (2014) Chih-Chien Chou et al. CANCER RESEARCH
- AMPK—Sensing Energy while Talking to Other Signaling Pathways
- (2014) D. Grahame Hardie Cell Metabolism
- A Novel MEK-ERK-AMPK Signaling Axis Controls Chemokine Receptor CCR7-dependent Survival in Human Mature Dendritic Cells
- (2014) Pilar López-Cotarelo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Metabolic-Stress-Induced Rearrangement of the 14-3-3 Interactome Promotes Autophagy via a ULK1- and AMPK-Regulated 14-3-3 Interaction with Phosphorylated Atg9
- (2014) V. K. Weerasekara et al. MOLECULAR AND CELLULAR BIOLOGY
- Kinase Regulation by Hydrophobic Spine Assembly in Cancer
- (2014) Jiancheng Hu et al. MOLECULAR AND CELLULAR BIOLOGY
- Kinases and Pseudokinases: Lessons from RAF
- (2014) A. S. Shaw et al. MOLECULAR AND CELLULAR BIOLOGY
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway
- (2014) Matthias Drosten et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations
- (2014) A. Yang et al. Cancer Discovery
- Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors
- (2014) Martin L. Sos et al. Cell Reports
- Energy Stress Regulates Hippo-YAP Signaling Involving AMPK-Mediated Regulation of Angiomotin-like 1 Protein
- (2014) Michael DeRan et al. Cell Reports
- Phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) is an AMPK target participating in contraction-stimulated glucose uptake in skeletal muscle
- (2013) Yang Liu et al. BIOCHEMICAL JOURNAL
- Pseudokinases from a structural perspective
- (2013) Susan S. Taylor et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin
- (2013) David B. Shackelford et al. CANCER CELL
- Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
- (2013) Nobuya Ishii et al. CANCER RESEARCH
- Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers
- (2013) Jiancheng Hu et al. CELL
- Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis
- (2013) J. Y. Guo et al. GENES & DEVELOPMENT
- Chemoproteomic Analysis of Intertissue and Interspecies Isoform Diversity of AMP-activated Protein Kinase (AMPK)
- (2013) Jiang Wu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- MEK and the inhibitors: from bench to bedside
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- B-Raf and the inhibitors: from bench to bedside
- (2013) Tiangui Huang et al. Journal of Hematology & Oncology
- Dysregulating IRES-Dependent Translation Contributes to Overexpression of Oncogenic Aurora A Kinase
- (2013) Tara Dobson et al. MOLECULAR CANCER RESEARCH
- Phosphorylation of BRAF by AMPK Impairs BRAF-KSR1 Association and Cell Proliferation
- (2013) Che-Hung Shen et al. MOLECULAR CELL
- AMPK-Dependent Degradation of TXNIP upon Energy Stress Leads to Enhanced Glucose Uptake via GLUT1
- (2013) Ning Wu et al. MOLECULAR CELL
- p53 status determines the role of autophagy in pancreatic tumour development
- (2013) Mathias T. Rosenfeldt et al. NATURE
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evidence for the role of AMPK in regulating PGC-1 alpha expression and mitochondrial proteins in mouse epididymal adipose tissue
- (2013) Zhongxiao Wan et al. Obesity
- Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma
- (2013) P. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Autophagy Sustains Mitochondrial Glutamine Metabolism and Growth of BrafV600E-Driven Lung Tumors
- (2013) A. M. Strohecker et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- PAF-Mediated MAPK Signaling Hyperactivation via LAMTOR3 Induces Pancreatic Tumorigenesis
- (2013) Sohee Jun et al. Cell Reports
- AMP-activated protein kinase: new regulation, new roles?
- (2012) David Carling et al. BIOCHEMICAL JOURNAL
- AMP-activated protein kinase phosphorylates and inactivates liver glycogen synthase
- (2012) Laurent Bultot et al. BIOCHEMICAL JOURNAL
- Coordinated time-dependent modulation of AMPK/Akt/mTOR signaling and autophagy controls osteogenic differentiation of human mesenchymal stem cells
- (2012) Aleksandar Pantovic et al. BONE
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo
- (2012) Brandon Faubert et al. Cell Metabolism
- First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
- (2012) M. Martinez-Garcia et al. CLINICAL CANCER RESEARCH
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway
- (2012) Carlotta Petti et al. MELANOMA RESEARCH
- Kinase Suppressor of Ras 2 (KSR2) Regulates Tumor Cell Transformation via AMPK
- (2012) M. R. Fernandez et al. MOLECULAR AND CELLULAR BIOLOGY
- The AMPK 2 Subunit Is Required for Energy Homeostasis during Metabolic Stress
- (2012) B. Dasgupta et al. MOLECULAR AND CELLULAR BIOLOGY
- AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress
- (2012) Sang-Min Jeon et al. NATURE
- Deregulated MYC expression induces dependence upon AMPK-related kinase 5
- (2012) Lidan Liu et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect
- (2012) Weiwei Yang et al. NATURE CELL BIOLOGY
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- AMPK functions as an adenylate charge-regulated protein kinase
- (2012) Jonathan S. Oakhill et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Amino acids and mTORC1: from lysosomes to disease
- (2012) Alejo Efeyan et al. TRENDS IN MOLECULAR MEDICINE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Pancreatic cancers require autophagy for tumor growth
- (2011) S. Yang et al. GENES & DEVELOPMENT
- Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
- (2011) J. Y. Guo et al. GENES & DEVELOPMENT
- Single Substitution within the RKTR Motif Impairs Kinase Activity but Promotes Dimerization of RAF Kinase
- (2011) Angela Baljuls et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
- (2011) Maria M. Mihaylova et al. NATURE CELL BIOLOGY
- AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
- (2011) Joungmok Kim et al. NATURE CELL BIOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF
- (2011) J. Hu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Raf Inhibitor Paradox: Unexpected Consequences of Targeted Drugs
- (2010) Adrienne D. Cox et al. CANCER CELL
- Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells
- (2010) Zhenfeng Zhang et al. CARCINOGENESIS
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Downregulation of AMPK Accompanies Leucine- and Glucose-Induced Increases in Protein Synthesis and Insulin Resistance in Rat Skeletal Muscle
- (2010) A. K. Saha et al. DIABETES
- From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
- (2010) Christophe Frémin et al. Journal of Hematology & Oncology
- Glucose Addiction of TSC Null Cells Is Caused by Failed mTORC1-Dependent Balancing of Metabolic Demand with Supply
- (2010) Andrew Y. Choo et al. MOLECULAR CELL
- Network organization of the human autophagy system
- (2010) Christian Behrends et al. NATURE
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
- (2010) D. F. Egan et al. SCIENCE
- Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
- (2009) Claudia Scholl et al. CELL
- KSR2 Is an Essential Regulator of AMP Kinase, Energy Expenditure, and Insulin Sensitivity
- (2009) Diane L. Costanzo-Garvey et al. Cell Metabolism
- The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch
- (2009) Amardeep S. Dhillon et al. CELLULAR SIGNALLING
- ERK and cell death: Mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence
- (2009) Sebastien Cagnol et al. FEBS Journal
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
- (2009) D. A. Ritt et al. MOLECULAR AND CELLULAR BIOLOGY
- Oncogenic B-RAF Negatively Regulates the Tumor Suppressor LKB1 to Promote Melanoma Cell Proliferation
- (2009) Bin Zheng et al. MOLECULAR CELL
- A dimerization-dependent mechanism drives RAF catalytic activation
- (2009) Thanashan Rajakulendran et al. NATURE
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within theDUSP6/MKP-3gene promoter
- (2008) Maria Ekerot et al. BIOCHEMICAL JOURNAL
- Hypothalamic CaMKK2 Contributes to the Regulation of Energy Balance
- (2008) Kristin A. Anderson et al. Cell Metabolism
- Muscarinic Receptor Activation of AMP-activated Protein Kinase Inhibits Orexigenic Neuropeptide mRNA Expression
- (2008) Claire Thornton et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of TBC1D1 as an Insulin-, AICAR-, and Contraction-stimulated Signaling Nexus in Mouse Skeletal Muscle
- (2008) Eric B. Taylor et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
- (2008) Dana M. Gwinn et al. MOLECULAR CELL
- Targeting EGFR in Colorectal Cancer
- (2008) Wells A. Messersmith et al. NEW ENGLAND JOURNAL OF MEDICINE
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More